Tyg, Oncoqr design new rocket to power pancreatic cancer 'warhead'
By Marie Powers
Friday, March 11, 2016
Tyg Oncology Ltd. and Oncoqr ML GmbH are relative newcomers to the field of cancer immunotherapy but their platforms are not. What's different now is that Tyg's lead vaccine candidate, TYG100, is powered by the S-TIR technology platform.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.